TOFA-PREDICT study protocol : a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease that affects up to 30% of patients with psoriasis. Current challenges in clinical care and research include personalised treatment, understanding the divergence of therapy response and unravelling the multifactorial pathophysiology of this complex disease. Moreover, there is an urgent clinical need to predict, assess and understand the cellular and molecular pathways underlying the response to disease-modifying antirheumatic drugs (DMARDs). The TOFA-PREDICT clinical trial addresses this need. Our primary objective is to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in PsA.
METHODS AND ANALYSIS: In this investigator-initiated, phase III, multicentre, open-label, four-arm randomised controlled trial, we plan to integrate clinical, molecular and imaging parameters of 160 patients with PsA. DMARD-naïve patients are randomised to methotrexate or tofacitinib. Additionally, patients who are non-responsive to conventional synthetic (cs)DMARDs continue their current csDMARD and are randomised to etanercept or tofacitinib. This results in four arms each with 40 patients. Patients are followed for 1 year. Treatment response is defined as minimal disease activity at week 16. Clinical data, biosamples and images are collected at baseline, 4 weeks and 16 weeks; at treatment failure (treatment switch) and 52 weeks. For the first 80 patients, we will use a systems medicine approach to assess multiomics biomarkers and develop a prediction model for treatment response. Subsequently, data from the second 80 patients will be used for validation.
ETHICS AND DISSEMINATION: The study was approved by the Medical Research Ethics Committee in Utrecht, Netherlands, is registered in the European Clinical Trials Database and is carried out in accordance with the Declaration of Helsinki. The study's progress is monitored by Julius Clinical, a science-driven contract research organisation.
TRIAL REGISTRATION NUMBER: EudraCT: 2017-003900-28.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
BMJ open - 12(2022), 10 vom: 10. Okt., Seite e064338 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kleinrensink, Nienke J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.10.2022 Date Revised 17.02.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2022-064338 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347316646 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347316646 | ||
| 003 | DE-627 | ||
| 005 | 20231226205402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2022-064338 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347316646 | ||
| 035 | |a (NLM)36216430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kleinrensink, Nienke J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TOFA-PREDICT study protocol |b a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.10.2022 | ||
| 500 | |a Date Revised 17.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease that affects up to 30% of patients with psoriasis. Current challenges in clinical care and research include personalised treatment, understanding the divergence of therapy response and unravelling the multifactorial pathophysiology of this complex disease. Moreover, there is an urgent clinical need to predict, assess and understand the cellular and molecular pathways underlying the response to disease-modifying antirheumatic drugs (DMARDs). The TOFA-PREDICT clinical trial addresses this need. Our primary objective is to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in PsA | ||
| 520 | |a METHODS AND ANALYSIS: In this investigator-initiated, phase III, multicentre, open-label, four-arm randomised controlled trial, we plan to integrate clinical, molecular and imaging parameters of 160 patients with PsA. DMARD-naïve patients are randomised to methotrexate or tofacitinib. Additionally, patients who are non-responsive to conventional synthetic (cs)DMARDs continue their current csDMARD and are randomised to etanercept or tofacitinib. This results in four arms each with 40 patients. Patients are followed for 1 year. Treatment response is defined as minimal disease activity at week 16. Clinical data, biosamples and images are collected at baseline, 4 weeks and 16 weeks; at treatment failure (treatment switch) and 52 weeks. For the first 80 patients, we will use a systems medicine approach to assess multiomics biomarkers and develop a prediction model for treatment response. Subsequently, data from the second 80 patients will be used for validation | ||
| 520 | |a ETHICS AND DISSEMINATION: The study was approved by the Medical Research Ethics Committee in Utrecht, Netherlands, is registered in the European Clinical Trials Database and is carried out in accordance with the Declaration of Helsinki. The study's progress is monitored by Julius Clinical, a science-driven contract research organisation | ||
| 520 | |a TRIAL REGISTRATION NUMBER: EudraCT: 2017-003900-28 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Magnetic Resonance Imaging | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a rheumatology | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Furans |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a tofacitinib |2 NLM | |
| 650 | 7 | |a 87LA6FU830 |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Perton, Frank T |e verfasserin |4 aut | |
| 700 | 1 | |a Pouw, Juliëtte N |e verfasserin |4 aut | |
| 700 | 1 | |a Vincken, Nanette L A |e verfasserin |4 aut | |
| 700 | 1 | |a Hartgring, Sarita A Y |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Mylène P |e verfasserin |4 aut | |
| 700 | 1 | |a Arbabi, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Foppen, Wouter |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Pim A |e verfasserin |4 aut | |
| 700 | 1 | |a Tekstra, Janneke |e verfasserin |4 aut | |
| 700 | 1 | |a Leijten, Emmerik F A |e verfasserin |4 aut | |
| 700 | 1 | |a Spierings, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Lafeber, Floris P J G |e verfasserin |4 aut | |
| 700 | 1 | |a Welsing, Paco M J |e verfasserin |4 aut | |
| 700 | 1 | |a Heijstek, Marloes W |e verfasserin |4 aut | |
| 700 | 0 | |a TOFA-PREDICT author group |e verfasserin |4 aut | |
| 700 | 1 | |a Tubergen, Astrid van |e investigator |4 oth | |
| 700 | 1 | |a Hermans, Kasper |e investigator |4 oth | |
| 700 | 1 | |a Vonkeman, Harold |e investigator |4 oth | |
| 700 | 1 | |a Hettema, Marthe |e investigator |4 oth | |
| 700 | 1 | |a Kok, Marc |e investigator |4 oth | |
| 700 | 1 | |a Bisoendial, Radjesh |e investigator |4 oth | |
| 700 | 1 | |a Kuijk, Arno van |e investigator |4 oth | |
| 700 | 1 | |a Wiegel, Jim |e investigator |4 oth | |
| 700 | 1 | |a Jansen, Tim |e investigator |4 oth | |
| 700 | 1 | |a Comarniceanu, Antoaneta |e investigator |4 oth | |
| 700 | 1 | |a Bon, Lenny Geurts-van |e investigator |4 oth | |
| 700 | 1 | |a Schipper, Lydia |e investigator |4 oth | |
| 700 | 1 | |a Bijnen, Sandra van |e investigator |4 oth | |
| 700 | 1 | |a Wijngaarden, Siska |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 12(2022), 10 vom: 10. Okt., Seite e064338 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:10 |g day:10 |g month:10 |g pages:e064338 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2022-064338 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 10 |b 10 |c 10 |h e064338 | ||